Main Hero Image
About Us Icon

PMZ 2123: Diabetic ketoacidosis


  • A biotechnology product that prevents the development of neurological complications in diabetic ketoacidosis patients.
  • Potential global market size of about $800 million.
  • Intravenous administration of PMZ-2123 prevents the development of cerebral edema in patients of diabetic ketoacidosis.
  • Efficacy has been demonstrated in animal models of diabetic ketoacidosis.
  • Chemistry, manufacturing and controls for PMZ-2123 are well established.
  • Patent titled “Method and Composition for Treating Diabetic Ketoacidosis” with Japanese Patent Application No. 2012-508762 has been issued.
  • Patents in other countries are pending.
  • PMZ-2123 has been safely used in humans as an investigational agent (NCT00115583; NCT00915070; NCT01658410).
  • PMZ-2123 has been safely used in humans as an investigational agent (NCT00115583; NCT00915070; NCT01658410).
  • Clinical stage – in preparation for human efficacy (Phase II) studies.
  • Link to publications